| 000 | 01256 a2200349 4500 | ||
|---|---|---|---|
| 005 | 20250514042541.0 | ||
| 264 | 0 | _c20020830 | |
| 008 | 200208s 0 0 eng d | ||
| 022 | _a0003-1453 | ||
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSpencer, Holly M | |
| 245 | 0 | 0 |
_aThe Rx-to-OTC switch of Claritin, Allegra, and Zyrtec: an unprecedented FDA response to petitioners and the protection of public health. _h[electronic resource] |
| 260 |
_bThe American University law review _cJun 2002 |
||
| 300 |
_a999-1050 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAnti-Allergic Agents |
| 650 | 0 | 4 | _aCetirizine |
| 650 | 0 | 4 | _aDrug Approval |
| 650 | 0 | 4 | _aDrug Costs |
| 650 | 0 | 4 | _aDrug Labeling |
| 650 | 0 | 4 |
_aDrug Prescriptions _xeconomics |
| 650 | 0 | 4 |
_aGatekeeping _xlegislation & jurisprudence |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLegislation, Drug |
| 650 | 0 | 4 | _aLoratadine |
| 650 | 0 | 4 |
_aNonprescription Drugs _xeconomics |
| 650 | 0 | 4 | _aPublic Health Practice |
| 650 | 0 | 4 |
_aTerfenadine _xanalogs & derivatives |
| 650 | 0 | 4 | _aUnited States |
| 650 | 0 | 4 |
_aUnited States Food and Drug Administration _xlegislation & jurisprudence |
| 773 | 0 |
_tThe American University law review _gvol. 51 _gno. 5 _gp. 999-1050 |
|
| 999 |
_c12079076 _d12079076 |
||